GnRH antagonists

被引:51
作者
Coccia, ME [1 ]
Comparetto, C [1 ]
Bracco, GL [1 ]
Scarselli, G [1 ]
机构
[1] Univ Florence, Dept Gynaecol Perinatol & Human Reprod, I-50129 Florence, Italy
关键词
GnRH-antagonisc; ovarian hyperstimulation; assisted reproduction techniques;
D O I
10.1016/j.ejogrb.2004.01.033
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian stimulation is an important step in the success rate of in vitro fertilization (IVF) allowing multiple follicular growth, several oocytes and consequently more embryos. The combination of GnRH-antagonists (GnRH-ant) and gonadotrophins is now available for clinical use and represent a valid alternative to classical protocol with GnRH agonist. GnRH-antagonists induce a direct block of GnRH receptor with a rapid decrease in LH and FSH, preventing LH surge. Two protocols has been designed for assisted reproduction technology (ART) treatment: multiple-dose protocol and a single-dose. Both protocols are simply, efficacious, started in the late follicular phase and do not have side effects. A review of GnRH-antagonist applications in ART cycles are presented. Smaller doses of gonadotrophins, shorter stimulation period and lower ovarian hyperstimulation syndrome (OHSS) incidence are reported in literature using GnRH-antagonist compared to agonist. Triggering of ovulation, the use in polycystic ovarian syndrome (PCOS) and poor reponders patients are other interesting indication. Regarding to pregnancy rate and potentially adverse effects of drugs on endometrium or implantation needed more data. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S44 / S56
页数:13
相关论文
共 65 条
[1]   Addition of GnRH antagonist in cycles of poor responders undergoing IVF [J].
Akman, MA ;
Erden, HF ;
Tosun, SB ;
Bayazit, N ;
Aksoy, E ;
Bahceci, M .
HUMAN REPRODUCTION, 2000, 15 (10) :2145-2147
[2]   GnRH antagonist in assisted reproduction: a Cochrane review [J].
Al-Inany, H ;
Aboulghar, M .
HUMAN REPRODUCTION, 2002, 17 (04) :874-885
[3]  
Al-Inany H, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001750, DOI 10.1002/14651858.CD001750, 10.1002/14651858.Cd001750]
[4]   Ovarian stimulation with HMG:: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [J].
Albano, C ;
Felberbaum, RE ;
Smitz, J ;
Riethmüller-Winzen, H ;
Engel, J ;
Diedrich, K ;
Devroey, P .
HUMAN REPRODUCTION, 2000, 15 (03) :526-531
[5]  
Albano C, 1996, HUM REPROD, V11, P2114
[6]   Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation [J].
Albano, C ;
Smitz, J ;
Camus, M ;
RiethmullerWinzen, H ;
VanSteirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1997, 67 (05) :917-922
[7]   Gonadotropin-releasing hormone antagonist: how good is the new hope? [J].
Albano, C ;
Platteau, P ;
Devroey, P .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2001, 13 (03) :257-262
[8]   The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetvorelix [J].
Albano, C ;
Grimbizis, G ;
Smitz, J ;
Riethmüller-Winzen, H ;
Reissmann, T ;
Van Steirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1998, 70 (02) :357-359
[9]   Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment [J].
Anderson, RA ;
Kinniburgh, D ;
Baird, DT .
HUMAN REPRODUCTION, 1999, 14 (10) :2665-2668
[10]  
[Anonymous], 1998, Hum Reprod, V13, P3023